HELICAL BIOSCIENCES LLC

Biotech

Lewy fold fibrils (LFFs), a recombinant research tool that models alpha-synuclein fibrils for Parkinson's disease and Lewy body dementia research

Grants
$396K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Commercial production of alpha-synuclein fibrils amplified from human postmortem brain tissue to expand the availability of a critical research tool for Parkinson's disease$395,951
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2589ZIPPIN BIO CORPORATION——
2590SIRPANT IMMUNOTHERAPEUTICS INC——
2591SACYL PHARMACEUTICALS, INC.——
2592HELICAL BIOSCIENCES LLC——
2593Dawah Pharmaceuticals, Inc.—$580K
2594Collidion Inc.—$575K
2595Animantis LLC—$550K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.